KALA BIO, Inc.
KALA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KALA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KALA
KALA BIO, Inc. is a biotechnology company transitioning from clinical-stage development of MSC-S therapies to an AI platform-as-a-service model after the failure of its lead candidate KPI-012.
Key risk: Cash runway risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for KALA BIO, Inc..
Similar companies
KALA BIO, Inc. is a biotechnology company transitioning from clinical-stage development of MSC-S therapies to an AI platform-as-a-service model after the failure of its lead candidate KPI-012.
- KALA BIO discontinued the CHASE Phase 2b trial of KPI-012 in September 2025 after it did not meet primary endpoints [sec_mda · as of 2026-04-15].
- The company is pivoting to an 'AI platform-as-a-service' model, offering on-premises AI infrastructure to biotech and pharma customers [sec_mda · as of 2026-08-19].
- Cash and equivalents were $0.2M as of 2026-06-30, with a net loss of $1.6M for the period [latest reported financials].
- Shareholders' equity stood at $7.0M as of 2026-06-30 [latest reported financials].
- The company expects to continue incurring significant operating losses and does not anticipate near-term revenue [sec_mda · as of 2026-04-15].
What works
- The company is leveraging substantial intellectual property and proprietary biological datasets from its legacy MSC-S program to build its AI platform [sec_mda · as of 2026-08-19].
- KALA BIO has resolved its obligations to Oxford Finance, reducing debt-related financial risk [sec_mda · as of 2026-08-19].
- The pivot to an AI platform-as-a-service model targets a growing market for dedicated AI infrastructure in biotech and pharma [sec_mda · as of 2026-08-19].
What to weigh
- The lead candidate KPI-012 failed its Phase 2b trial, leading to discontinuation of the entire MSC-S platform [sec_mda · as of 2026-04-15].
- Cash reserves are very low ($0.2M as of 2026-06-30), raising significant going-concern risk [latest reported financials].
- The company has no approved products or revenue-generating operations and expects continued operating losses [sec_mda · as of 2026-04-15].
- The AI platform-as-a-service model is in early stages and unproven, with no disclosed customer contracts or revenue [sec_mda · as of 2026-08-19].
From the filings
Quoted directly from source documents.
KPI-012 failed its Phase 2b trial and was discontinued
“By September 2025, the CHASE trial did not meet its primary endpoints, and we determined to discontinue our development of KPI-012 and the MSC-S platform.”
SEC MD&A · April 15, 2026
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash of $0.2M as of 2026-06-30 is extremely low, likely insufficient to fund operations beyond the near term [latest reported financials].
- No approved products or revenue — The company has no revenue-generating products and expects to continue incurring significant operating losses [sec_mda · as of 2026-04-15].
- Unproven business model pivot — The AI platform-as-a-service model is in early stages with no disclosed customers or revenue, creating execution risk [sec_mda · as of 2026-08-19].
- Clinical trial failure — The failure of KPI-012 in Phase 2b led to discontinuation of the entire MSC-S platform, eliminating the primary pipeline [sec_mda · as of 2026-04-15].
What to watch
- Progress in securing customers or partnerships for the AI platform-as-a-service model [sec_mda · as of 2026-08-19].
- Any financing or capital-raising activities given the low cash position [latest reported financials].
- Potential monetization of legacy MSC-S assets or intellectual property [sec_mda · as of 2026-08-19].
- Updates on the company's ability to continue as a going concern [sec_mda · as of 2026-04-15].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run KALA BIO, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available KALA BIO, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
15.4 months
D/E 0.17 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$244K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 417,517 | $72K |
| citadel advisors llc | 281,650 | $49K |
| geode capital management, llc | 261,061 | $45K |
| adar1 capital management, llc | 141,480 | $24K |
| vanguard capital management llc | 121,098 | $21K |
| jane street group, llc | 36,000 | $6K |
| vanguard fiduciary trust co | 29,628 | $5K |
| state street corp | 28,576 | $5K |
| grant private wealth management inc | 20,000 | $3K |
| lpl financial llc | 17,229 | $3K |
Showing top 10 of 24 institutional holders of KALA BIO, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 0.1%
- Days to cover
- 0.3
- Shares short
- 1,058,718
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KALA short interestGovernance
Frequently asked questions
What is the AI investment thesis for KALA BIO, Inc.?
KALA BIO, Inc. is a biotechnology company transitioning from clinical-stage development of MSC-S therapies to an AI platform-as-a-service model after the failure of its lead candidate KPI-012.
What is KALA BIO, Inc.'s lead drug candidate?
KALA BIO, Inc.'s most advanced tracked candidate is KPI-012 (Phase 2) for Persistent Corneal Epithelial Defect.
Who is the CEO of KALA BIO, Inc.?
Mr. Avi Minkowitz is the chief executive officer of KALA BIO, Inc. (KALA).
Where is KALA BIO, Inc. headquartered?
KALA BIO, Inc. (KALA) is headquartered in Arlington, MA, United States.
What therapeutic areas does KALA BIO, Inc. focus on?
KALA BIO, Inc. develops therapies across Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.